BioLine RX Ltd - ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
BLRX Nasdaq 8731 https://www.biolinerx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioLine RX Ltd - ADR

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting - Apr 17th, 2024 11:00 am
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement - Apr 10th, 2024 11:00 am
BioLineRx Announces $6 Million Registered Direct Offering - Apr 1st, 2024 1:00 pm
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript - Mar 27th, 2024 4:23 pm
BLRX: First Aphexda Sales Recognized - Mar 27th, 2024 9:39 am
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates - Mar 26th, 2024 11:00 am
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 - Mar 20th, 2024 11:00 am
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production - Mar 4th, 2024 12:00 pm
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) - Feb 28th, 2024 12:00 pm
BLRX: Poster Presentations - Feb 26th, 2024 1:27 pm
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond - Feb 25th, 2024 7:12 pm
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR® - Feb 16th, 2024 12:00 pm
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease - Dec 21st, 2023 12:00 pm
BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript - Nov 21st, 2023 8:45 pm
BLRX: A Series of Fortunate Events - Nov 21st, 2023 9:57 am
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates - Nov 20th, 2023 12:00 pm
BioLineRx to Report Third Quarter 2023 Results on November 20, 2023 - Nov 13th, 2023 12:00 pm
3 Tech Stocks That Wall Street Loves More Than Nvidia - Nov 2nd, 2023 7:12 pm
BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures - Oct 31st, 2023 1:00 pm
3 Top Penny Stocks to Make You a Millionaire in 5 Years - Oct 30th, 2023 3:38 pm